Show Notes
Rheumatoid arthritis is often seen as “just” joint pain, but Mayo Clinic rheumatologist Dr. John Davis and University of Colorado researcher Dr. Kevin Deane reveal a far more complex and promising story. In this episode of Tomorrow’s Cure, host and journalist Cathy Wurzer explores how autoimmune disease can quietly develop for years before the first swollen joint, and how new blood tests, gut microbiome insights, and the exposome, our lifetime of environmental exposures such as cigarette smoke and wildfire haze, are helping clinicians see risk much earlier.
The conversation dives into emerging tools that use artificial intelligence to sift through genetics, autoantibodies, microbiome data, and real-world exposures to predict who is most likely to develop rheumatoid arthritis and who will respond to specific treatments. Hear how prevention trials, lessons from type 1 diabetes, and more virtual models of care could change what it means to live with, or even avoid, rheumatoid arthritis in the future.
How to listen and stay connected:
Subscribe to Tomorrow’s Cure on your favorite podcast app and follow the show so you never miss an episode.
Get the latest health information from Mayo Clinic’s experts—subscribe to Mayo Clinic’s newsletter for free today: https://mayocl.in/3EcNPNc
Connect with Mayo Clinic:
Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/
Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/
Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic
Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic
More from Tomorrow's Cure
How could Mayo Clinic’s Global AI Platform transform personalized care?
What if transplant patients could one day live free from lifelong anti-rejection drugs?
What happens when multiple sclerosis symptoms mask a different condition?
What if repairing damaged cartilage could be done in a single procedure? Using your own cells and the healing signals they need to recover?
What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda’s 16‑year survivorship story and Dr. Smoot’s lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors.